NEW YORK (GenomeWeb News) – Interleukin Genetics said today that it has signed up Labec Pharma of Madrid to distribute its genetic test for heart attack risk in Spain and Portugal.

The Cardio Health test identifies multiple genetic variations that can lead to overproduction of certain chemicals that can cause inflammation, and can indicate "a statistically significant risk" for heart attack, the Waltham, Mass.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.